Johnson & Johnson (JNJ) reports earnings Tuesday morning for the third quarter, with analysts expecting the company's revenue and profit to rise year-on-year.

Analysts see Johnson & Johnson reporting $22.21 billion in revenue, 4% above last year's $21.35 billion in the same quarter, according to estimates compiled by Visible Alpha. 澳洲幸运5官方开奖结果体彩网:Net income is expected to fall to $4.07 billion from $4.31 billion.

In the third quarter of 2023, Johnson & Johnson also posted a $21 billion one-time gain for discontinuing operations, as it 澳洲幸运5官方开奖结果体彩网:completed the spinoff of its consumer products division, including products like Tylenol and Band-Aids, 澳洲幸运5官方开奖结果体彩网:into its own public company called Kenvue (KVUE).

Key Metri♚c: Updated Outlook After V-Wave Aꦺdjustment

The company has shifted its 澳洲幸运5官方开奖结果体彩网:full-year outlook in each of its first two quarters, and recently said it expects to do so again. 澳洲幸运5官方开奖结果体彩网:In the first quarter, the company narrowed its full-year sales and profit estimates, and in the second quarter lifted its sales estimates while lowering profit projections to account for recent 澳洲幸运5官方开奖结果体彩网:acquisitions.

Last Wednesday, the pharmaceutical and medical device company said it will provide a new update after announcing this week the closing of its acquisition of V-Wave, which develops a number of treatments for heart failure. It 澳洲幸运5官方开奖结果体彩网:announced the deal, valued at up to $1.7 billion, in August.

Business Spotlight: Drug Pipeline, Acquisitions

The V-Wave acquisition is one of several the company has announced this year, as it has spent billions to expand its portfolio of drugs across a number of 澳洲幸运5官方开奖结果体彩网:segments like cancer treatment and 澳洲幸运5官方开奖结果体彩网:cardiovascular health.

Johnson & Johnson currently has about 100 drugs in its development pipeline, from varying stages of clinical trials up to those having been submitted to the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) or international regulators.

Johnson & Johnson stock was little changed Thursday at $160.51. The shares are a bit m༺ore than 2% higher than they were to start the year.

UPDATE🍸—This story has been updated with the latest estimates.